{"id": "1364968401324630023", "creation": 1614268801.0, "user_id": "1336785654018138115", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 2, "reply_count": 0, "like_count": 7, "quote_count": 2}}, "text": "Based on our intranasally administered, replication-deficient adenovirus #vaccine platform, our #COVID19 vaccine candidate AdCOVID is easy to use &amp; has the potential to block transmission. We\u2019re looking forward to phase 1 results. Full release: https://t.co/7uR8P1MsXV https://t.co/I6dwR652KI", "first_save": 1634559108.199414, "hashtags": ["#VACCINE", "#COVID19"]}